Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2005-06-14
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S443000, C514S444000, C514S468000, C514S601000, C514S602000, C514S603000, C514S604000, C514S605000
Reexamination Certificate
active
06906092
ABSTRACT:
The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula IMore particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
REFERENCES:
patent: 3845097 (1974-10-01), Toyoshima et al.
patent: 3850968 (1974-11-01), Toyoshima et al.
patent: 3919291 (1975-11-01), Toyoshima et al.
patent: 4066773 (1978-01-01), Okamoto et al.
patent: 4097472 (1978-06-01), Okamoto et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5665764 (1997-09-01), Hupe et al.
patent: 5948780 (1999-09-01), Peterson et al.
patent: 6207698 (2001-03-01), Wantanabe et al.
patent: 20 65 966 (1977-07-01), None
patent: 2065966 (1977-07-01), None
patent: 20 65 966 (1978-11-01), None
patent: 183271 (1985-11-01), None
patent: 183271 (1986-06-01), None
patent: 0 183 271 (1990-05-01), None
patent: 0 606 046 (1994-07-01), None
patent: 606046 (1994-07-01), None
patent: 0 606 046 (1997-10-01), None
patent: 51105048 (1976-09-01), None
patent: 0 183 271 (1985-11-01), None
patent: WO 96/38434 (1996-12-01), None
patent: 96 38434 (1996-12-01), None
patent: WO 96 38434 (1996-12-01), None
patent: 97 19068 (1997-05-01), None
patent: WO 97 19068 (1997-05-01), None
patent: WO 97/19068 (1997-05-01), None
patent: 97 27174 (1997-07-01), None
patent: WO 97/27174 (1997-07-01), None
patent: WO 97 27174 (1997-07-01), None
Polman, C.H. et al, BMJ 2000, 321, 490-4.
Cohen, J.A. et al, J. Neuroimmun., 1999, 98 29-36.
Chemical Abstracts document No. 86:30073, 1976.
Dubois B, D'Hooghe MB, De Lepeleire K, Ketelaer P, Opdenakker G, Carton H., Mult Scler Apr. 1998;4(2):74-8, cited in PMID: 9599337.
“Cecil Textbook of Medicine, 20th Edition”, Bennett, J.C. Editor, W.B. Saunders, Philadephia, 1996, pp. LVIII-LIX.
“Merck Manual Diagnosis and Therapy, 16th Edition”, Berkow, R. Editor-in-Chief, Merck Research Laboratories, Rahway, N.J., 1992, pp. 2792-2793.
Skiles, J.W. et al, Annual Reports in Medical Chemistry, vol. 35, Academic Press, San Diego, 2000, pp. 167-176.
Abdel-Ghaffer, et al. “Synthesis of Biologically Active Fluorene-2-sulphonylamino Acid and Dipeptide Derivatives”, J. Serb. Chem. Soc., vol. 55, No. 6, 1990, pp 311-317.
El-Naggar et al., “Synthesis and Biological Activity of Some New Dibenzofuran and 7-Nitrodibenzofuran-2-sulphonylamino Acid Derivatives”, V-35, Acta Pharm. Jugosl., 1985, 15-22.
Bennett, J.C. Editor, “Cecil Textbook of Medicine, 20thEdition”, W.B. Saunders, Philadelphia, 1996, pp. LVIII-LIX.
Berkow, R., Editor-in-Chief, “Merck Manual of Diagnosis and Therapy, 16thEdition”, Rahway, NJ, 1992, 270=92-2793.
Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Chemistry, vol. 31”, 1996, Academic Press, San Diego, p241-246.
Summers, J.B. et al, in “Annual Reports in Medicinal Chemistry, vol. 33”, 1998, Academic Press, San Diego, p 131-140.
Kikumoto, Ryoji; Tamao, Yoshikuni; Ohkubo, Kazuo; Tezuka, Tohru; Tonomura, Shinji; Okamoto, Shosuke; Funahara, Yoshinori; Hijikata, Akiko, J. Med. Chem., 23(8), 1980, 830-6 (English).
Abdel-Ghaffar, et al.,J. Serb. Chem. Soc., Synthesis of Biologically Active Fluorene-2-Sulphonylamino Acid and Dipeptide Derivatives, vol. 55, No. 6, 1990, pp. 311-317.
El-Naggar et al.,Acta Pharm. Jugosl. Synthesis and Biological Activity of Some New Dibenzofuran-and 7-Nitrodibenzofuran-2-Sulphonylamino Acid Derivatives, V-35, 1985, PP 15-22.
Abdel-Ghaffar, et al., “Synthesis of Biologically active fluoren-2-sulfonylamino acid and dipeptide derivatives” J. Serb. Chem. Soc., vol. 55, No. 6, 1990, pp. 311-317.
El-Naggar et al., “Synthesis and biological activity of some new dibenzofuran and 7-nitrodibenzofuran-2-sulphonylamino acid derivatives” ACTA Pharm, Jugosl., vol. 135, 1985, pp. 15-22.
O'Brien Patrick Michael
Picard Joseph Armand
Sliskovic Drago Robert
White Andrew David
Ashbrook Charles W.
Jones Dwayne
Pfizer Inc.
Purchase, Jr. Claude F.
Warner-Lambert & Company
LandOfFree
Method of inhibiting matrix metalloproteinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting matrix metalloproteinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting matrix metalloproteinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3506777